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Background: The long allele of a functional promoter polymorphism in the serotonin transporter
(SERT) is associated with an increased risk of some forms of pulmonary arterial hypertension. We
hypothesized that the long allele or other polymorphisms in SERT would be associated with an
increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease.
Methods: We performed a multicenter case-control study. Subjects undergoing liver transplant
evaluation at seven centers were prospectively screened for the presence of PPHTN using
transthoracic echocardiography. PPHTN was confirmed by right heart catheterization using
standard criteria.
Results: The study sample included 30 case patients with PPHTN and 109 control subjects with
advanced liver disease. There was no significant association between the long allele and case
status in an adjusted additive model (odds ratio, 0.63; 95% confidence interval, 0.33 to 1.21;
p  0.17). If anything, LL genotype tended to be associated with a lower risk of PPHTN. There
were no associations between other SERT polymorphisms and PPHTN.
Conclusions: SERT polymorphisms are not associated with the risk of PPHTN in patients with
advanced liver disease. Other clinical or genetic risk factors may play a role in this complication
of portal hypertension. (CHEST 2009; 135:1470–1475)
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P ulmonary arterial hypertension (PAH) is presentin approximately 6% of individuals evaluated for
liver transplantation, termed portopulmonary hyper-
tension (PPHTN).1 The risk of death for individuals
with PPHTN is greater than that for those with
either PAH or portal hypertension alone.2,3 Further-
more, PPHTN presents a high risk of death during
orthotopic liver transplantation, often precluding the
only curative option for hepatic failure.4 Early iden-
tification of this complication of portal hypertension
not only is critical to the management of individual
patients, but it also has implications regarding the
appropriate allocation of scarce organ resources.
Serotonin plays a key role in the proliferative and
vasomotor phenotype of pulmonary vascular endo-
thelial and smooth muscle cells. In addition to
serotonin signaling via cell surface receptors, modu-
lation of intracellular serotonin levels by the seroto-
nin transporter (SERT) mediates the effects of this
molecule.5 Interest in a potential pathogenetic link
between SERT and PAH followed observation of an
increased incidence of PAH among users of the
anorexigens aminorex and fenfluramine, substrates
for SERT.6,7 It has been subsequently shown that
transgenic mice overexpressing SERT demonstrate in-




Similarly, the administration of SERT inhibitors pre-
vents hypoxic-induced pulmonary vascular remodeling
in wild-type animals.10
An insertion/deletion polymorphism (in/del) in the
gene-encoding SERT modulates both gene expres-
sion and protein function, with the long allele asso-
ciated with significantly higher gene transcription
and transporter activity than the short allele.11 In
2001, investigators reported that individuals with
idiopathic pulmonary arterial hypertension (IPAH)
were much more likely to possess an long allele than
were normal control subjects. They went on to
demonstrate that the long allele was associated with
higher levels of SERT messenger RNA and protein
in the lungs of these individuals.12 Subsequent re-
ports linking the SERT polymorphism with pulmo-
nary hypertension in individuals with COPD and left
heart failure strengthened the theory that genetic
variation in SERT contributed to pulmonary vascular
disease.13,14 However, attempts to replicate the ini-
tial association between the long allele and PAH
were unsuccessful in distinct populations of IPAH
and familial PAH.15,16 No data are available regard-
ing patients with the many different forms of PAH
associated with other conditions, such as PPHTN.
We therefore aimed to determine whether the
long allele of the promoter polymorphism or other
single-nucleotide polymorphisms (SNPs) in SERT is
associated with the occurrence of PPHTN in patients
with portal hypertension.
Materials and Methods
Study Design and Subjects
The Pulmonary Vascular Complications of Liver Disease study
enrolled a cohort of 536 patients evaluated for liver transplanta-
tion at seven centers in the United States between 2003 and
2006. The only inclusion criterion was the presence of chronic
portal hypertension with or without intrinsic liver disease. We
excluded patients with evidence of active infection, recent ( 2
weeks) GI bleeding, or who had undergone liver or lung trans-
plantation. The institutional review boards at each of the partic-
ipating centers approved this study, and informed consent was
obtained.
We performed a case-control study within the Pulmonary
Complications of Liver Disease study cohort. The study sample
included newly referred patients who were evaluated with trans-
thoracic echocardiography during the study period. “Prevalent”
patients who met the case definition (see “Case and Control
Definitions” section) were also included. Only subjects with
analyzable genetic material were included. We excluded patients
with pulmonary function test results showing a significant ob-
structive ventilatory defect, which was defined as an FEV1/FVC
ratio  0.70 with FEV1 of  80% predicted, and/or a significant
restrictive ventilatory defect, which was defined as FVC and (if
performed) total lung capacity of  70% predicted. Patients who
otherwise fulfilled the case definition (see “Case and Control
Definitions” section) without pulmonary function testing were
included if chest radiography did not show hyperinflation or
interstitial lung disease; control subjects without pulmonary
function testing were excluded. The study sample also excluded
patients with HIV infection and the presence of more than
moderate aortic or mitral valvular disease or significant left
ventricular dysfunction by echocardiography. Severity of liver
disease was assessed using the Model for End-stage Liver
Disease score, a validated scoring system for chronic liver
disease.17,18
Screening with transthoracic echocardiography was standard
for liver transplant candidates during the study period. A trans-
thoracic echocardiogram showing right ventricular (RV) systolic
pressure  50 mm Hg with or without abnormal RV morphology
was considered an indication for right heart catheterization. RV
morphology was graded in a fashion consistent with the guide-
lines of the American Society of Echocardiography.19
Case and Control Definitions
Case patients with PPHTN met the following criteria: (1) mean
pulmonary artery pressure  25 mm Hg, pulmonary capillary
wedge pressure (or left ventricular-end diastolic pressure)  15
mm Hg, and pulmonary vascular resistance  240 dyne  s  cm–5;
and (2) exclusion of other forms of pulmonary hypertension.20
Prevalent case patients who had previously undergone evaluation
and were subsequently being treated were also included; data
from the initial evaluation (pretreatment) were used for these
case patients. Control subjects met the following echocardio-
graphic criteria: (1) RV systolic pressure  40 mm Hg (if capable
of being estimated); and (2) absence of right atrial or ventricular
abnormalities.
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Genotyping
Genomic DNA was isolated from peripheral leukocytes using
standard procedures (Gentra Puregene; Qiagen, Inc; Valencia,
CA). The SERT promoter polymorphism was genotyped using
published primers and amplification protocols;21 products were
sized using agarose gel and classified using the diallelic L-S
system. SNP genotyping was performed using a commercial assay
(GoldenGate Assay; Illumina, Inc; San Diego, CA). Seven repli-
cate DNA samples showed 100% reproducibility of genotypes,
and all polymorphisms were successfully genotyped in the 139
study subjects.
SNP Selection
Seven SNPs from a 46-kilobase region on chromosome 17
centered on SERT (NM001045) were identified from public
(dbSNP and HapMap) and private (Illumina) databases (Table
1). The following criteria were used for SNP selection: (1) minor
allele frequency  0.05; (2) haplotype tagging SNPs (HapMap
CEU); and (3) interlocus spacing of approximately 5 kilobases.
To detect population stratification we genotyped an additional
set of 60 SNPs, representing null loci. These were selected from
a validated list of Ancestry Informative Markers22 using the
following criteria: (1) minor allele frequency  10%; (2) mini-
mum of 20 Mb between loci; and (3) no linkage (r2  0.2)
between null and SERT loci. The physical and genetic map
positions of the null loci are available from the authors by
request.
Statistical Analysis
Unpaired Student t tests, rank sum tests, 2 tests, and Fisher
exact tests were used, as appropriate. Genotype analyses were
performed using additive logistic regression models with terms
for gender and a diagnosis of autoimmune hepatitis included in
the final models. Single-locus association analyses were per-
formed using a statistical software package (SAS/STAT; SAS
Institute; Cary, NC). A p value  0.05 was considered to be
significant. Pairwise linkage disequilibrium between loci (D and
r2) and Hardy Weinberg equilibrium were assessed using appro-
priate software (Haploview, version 4.0; Broad Institute; Cam-
bridge, MA).23 The potential for population stratification was
assessed by comparing allele frequencies of the null loci between
case patients and control subjects using the 2 test with a
significance threshold of p  0.05.24
Our sample size provided  95% power (  0.05) to detect
the association between the long allele and PAH shown previ-
ously.12 In the event that the association between the long allele
and PPHTN was smaller, we still had 80% power to detect an
odds ratio (OR) of 2.36. Power analysis was performed using
appropriate software (Quanto, version 1.2; University of Southern
California; Los Angeles, CA).25
Results
There were 175 patients who met case or control
criteria, and 30 case patients with PPHTN and 109
control subjects with liver disease with analyzable
genetic material in the study sample. There were no
differences in age, gender, race, or Model for End-
stage Liver Disease score between the final study
sample and excluded patients without genetic mate-
rial (data not shown).
Age and severity of liver disease were similar
between case patients and control subjects (Table 2).
Female gender, autoimmune hepatitis, and hepatitis
C infection were associated with the risk of PPHTN,
as we have previously reported.26
Genotype distribution for all SERT polymorphisms
was in Hardy-Weinberg equilibrium (p  0.05). There
was no association between SERT in/del genotype and
case status (Table 3). Contrary to our hypothesis, the
long allele was (if anything) associated with a lower
risk of PPHTN after adjustment for gender and
autoimmune liver disease (adjusted OR, 0.63; 95%
CI, 0.33 to 1.21; p  0.17). Similarly, there were no
associations between case status and the seven SNPs
in and around SERT (Table 4). Pairwise assessment
of linkage disequilibrium (a measurement of shared
ancestry between neighboring polymorphisms) dem-
onstrated two distinct blocks in the genomic region
of SERT. The first block, comprised of six SNPs
(pairwise D  0.80), encompassed the coding re-
gion of SERT. The second block, containing the
tightly linked in/del and rs2020933 (D  0.85), was
independent of the first block (D  0.34). Thus,
in/del genotype is not an accurate proxy for genetic
variation throughout the gene encoding SERT. Fig-
ure 1 depicts these relationships between the poly-
morphisms genotyped in this study.
There were no significant differences in null loci
allele frequencies between case patients and control
subjects, and all were in Hardy Weinberg equilib-
rium (data not shown).
Discussion
This is the first case-control study of SERT-related
genetic risk factors for PPHTN. The long allele of
the SERT in/del polymorphism was not associated
with case status in our population. On the contrary,
there was a trend toward a lower risk of PPHTN in
patients with this allele. In addition, we did not find
associations between other polymorphisms in SERT
and the risk of PPHTN.
Table 1—Genotyped Serotonin Transporter
Polymorphisms
Locus Chromosome Position Location Alleles
in/del 25588111 Promoter Short/long
rs2020933 25585881 Intron 0 A/T
rs2020936 25574940 Intron 0 C/T
rs6354 25574024 Exon 2 A/C
rs2020942 25571040 Intron 3 G/A
rs140701 25562658 Intron 9 G/A
rs1042173 25549137 Exon 15 T/G
rs7224199 25547852 3’ G/T
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Our findings add to the knowledge of the contro-
versial relationship between SERT and PAH. Dem-
onstration of an association between possession of
the long allele in the SERT in/del and presence of
IPAH12 generated interest in the serotonergic con-
tribution to PAH, and offered the first common
genetic risk factor for the disease. Subsequent at-
tempts to replicate these findings in larger, geo-
graphically distinct cohorts of PAH patients were
unsuccessful.15,16 Similarly, although plasma seroto-
nin levels were increased in PAH patients in older
studies,27,28 they were not increased in a more recent
study that included patients with PPHTN.29 Possible
explanations for these discrepant findings include
population differences between studies, the exis-
tence of additional causal genetic variants in SERT,
pathogenetic contributions from redundant mecha-
nisms with serotonin signaling pathways, or type I
error. Thus, the true nature of the role of serotonin
signaling in PAH pathogenesis remains cryptic.
Table 3—SERT in/del Genotype in PPHTN Case





(n  109) p Value*
SS 8 (27%) 26 (24%) 0.17
LS 18 (60%) 54 (50%)
LL 4 (13%) 29 (27%)
*Additive logistic regression model of PPHTN case status with
genotype, adjusted for gender and autoimmune liver disease.
Table 4—Logistic Regression of PPHTN Case Status
with Genotype (Additive Models, Adjusted for Gender
and Autoimmune Liver Disease)
Locus OR 95% CI p Value
in/del 0.63 0.43–1.21 0.17
rs2020933 2.08 0.47–9.19 0.33
rs2020936 0.89 0.45–1.78 0.75
rs6354 0.92 0.47–1.81 0.81
rs2020942 0.83 0.44–1.56 0.56
rs140701 1.16 0.64–2.08 0.63
rs1042173 0.95 0.53–1.68 0.86
rs7224199 0.98 0.56–1.73 0.95





(n  109) p Value
Age, yr 54  10 53  9 0.55
Female gender 20 (67) 43 (40) 0.008
Race 0.24
White 28 (93) 97 (89)
Black 0 8 (7)
Other 2 (7) 4 (4)
Etiology of portal hypertension
Alcohol 13 (43) 48 (44) 0.95
Hepatitis C infection 5 (17) 57 (52) 0.001
Autoimmune hepatitis 7 (23) 4 (4) 0.002
Nonalcoholic fatty liver disease 1 (3) 8 (75) 0.68
Hepatitis B infection 1 (3) 6 (6) 1.0
Primary sclerosing cholangitis 1 (3) 9 (8) 0.69
Primary biliary cirrhosis 3 (10) 3 (3) 0.12
Cryptogenic 2 (7) 8 (7) 1.0
Model for End-stage Liver Disease score† 12  3 13  5 0.86
Echocardiography
RV dilation 24 (80) 0 0.001
RV hypertrophy‡ 11 (39) 0 0.001
RV dysfunction 17 (59) 0 0.001
RV systolic pressure,§ mm Hg 77  26 31  5 0.001
Invasive hemodynamics
Mean right atrial pressure, mm Hg 9  6
Mean pulmonary artery pressure, mm Hg 50  9
Pulmonary capillary wedge pressure, mm Hg 10  4
Cardiac index, L/min/m2 2.9  0.9
Pulmonary vascular resistance, dyne  s  cm–5 672  376
*Variables are given as the mean  SD or No. (%), unless otherwise indicated.
†Data available for 28 case patients and 108 control subjects.
‡Data available for 28 case patients and 104 control subjects.
§Right ventricular systolic pressure estimable in 27 case patients and 45 control subjects.
Mean atrial pressure was measured in 29 case patients.
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There are several potential explanations for the
negative findings in our study. First, inadequate
power is always a concern (type II error). Our study
had more than sufficient power to detect the strong
association previously reported in IPAH.12 Coupled
with the trend toward the LL genotype being pro-
tective, this explanation is unlikely. Second, con-
founding by other genetic differences between case
patients and control subjects could have masked an
association. The absence of population stratification
demonstrated by the null loci results makes this less
likely. Third, it is possible that the in/del polymor-
phism serves as a marker of the true causal genetic
variant in SERT in some populations, but not in ours,
because our analysis found that the in/del polymor-
phism was not linked to genetic variation in the
coding region. Fourth, SERT in/del genotype may
contribute to an intermediate phenotype in patients
with advanced liver disease, not captured by our
study. Last, PPHTN and idiopathic forms of the
disease could result from different pathogenetic mech-
anisms. We believe that these data demonstrate that
PPHTN is independent of genetic variation in SERT.
Limitations of this multicenter study include the
use of transthoracic echocardiography as a screening
modality. This technique is subject to interobserver
variability in performance and interpretation as well
as technical limitations specific to individual sub-
jects. In addition, missing data may lead to misclas-
sification of case patients and control subjects. This
could have resulted in bias to the null, although we
used strict accepted criteria for both case patients
and control subjects to minimize this possibility.
This is the first reported candidate genetic associ-
ation study in a well-phenotyped and prospectively
recruited cohort of subjects with portal hypertension
and PAH. We have shown that common genetic
variation in SERT does not account for the risk of
PPHTN in patients with advanced liver disease.
Future studies should focus on other mechanistic
components of this disease.
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